-- Bio-Path Holdings Inc. (NASDAQ: BPTH) reported a loss of $3.24 share for the full year 2019, narrower than a loss of
Bio-Path Holdings (NASDAQ: BPTH): 2019 Earnings Snapshot
Categories
Biotechnology
Aurinia Pharmaceuticals (NASDAQ: AUPH): Q4 2019 Earnings Snapshot
-- Aurinia Pharmaceuticals (NASDAQ: AUPH) reported a fourth-quarter 2019 loss of $0.78 per share versus a loss of $0.14 per share expected.
Amicus Therapeutics (FOLD): FY 2019 Earnings Snapshot
-- Biotechnology company Amicus Therapeutics (NASDAQ: FOLD) reported a net loss of $356.4 million or $1.48 per share for fiscal 2019, compared
Sage Therapeutics (SAGE) Q4 2019 Earnings Snapshot
-- Sage Therapeutics (NASDAQ: SAGE) reported fourth quarter 2019 loss of $3.25 per share vs. expected loss per share of $3.61. --
ACADIA Pharmaceuticals (ACAD): Q4 2019 Earnings Snapshot
-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) reported Q4 2019 loss of $0.34 per share, vs. $0.36 expected. -- Revenue grew 65% to
Sarepta Therapeutics (SRPT): Q4 2019 Earnings Snapshot
-- Sarepta Therapeutics, Inc. (NASDAQ: SRPT) reported a loss of $1.57 per share in the fourth quarter of 2019, vs $1.86 per share loss expected.
Moderna (MRNA) ships coronavirus vaccine candidate for trials, shares hit a peak
Shares of Moderna Inc. (NASDAQ: MRNA) soared to a record high of $29.98 on Wednesday after shipping the first coronavirus vaccine candidate
Amarin Corporation (AMRN): Q4 2019 Earnings Snapshot
— Amarin Corporation plc (NASDAQ: AMRN) reported earnings of $0.04 per share in the fourth-quarter 2019 vs. $0.02 per share loss expected. — Revenue grew
MannKind Corporation (MNKD): Q4 2019 Earnings Snapshot
-- MannKind Corporation (NASDAQ: MNKD) reported Q4 2019 loss of $0.07 per share, vs. a loss of $0.07 expected. -- Total revenue
Intercept Pharmaceuticals (NASDAQ: ICPT): Q4 2019 Earnings Snapshot
-- Intercept Pharmaceuticals (NASDAQ: ICPT) reported a fourth-quarter 2019 loss of $2.99 per share versus a loss of $2.67 per share expected.
Clovis Oncology (NASDAQ: CLVS): Q4 2019 Earnings Snapshot
-- Clovis Oncology (NASDAQ: CLVS) reported a fourth-quarter 2019 loss of $1.81 per share versus a loss of $1.71 per share expected.
Excitement continues for BioXcel Therapeutics (BTAI) investors
Once again, the shares of BioXcel Therapeutics (NASDAQ: BTAI) surpassed its previous 52-week high today and closed at $39.59, up 7.09%. BTAI
Medtronic (MDT) beats Q3 earnings estimates; revenues miss mark
Medtronic plc (NYSE: MDT) topped earnings expectations for the third quarter of 2020 while revenue fell short of estimates. The stock was
Immunogen Inc (NASDAQ:IMGN) Q4 2019 Earnings Call Transcript
Immunogen Inc (IMGN) Q4 2019 earnings call dated Feb 14, 2020 Corporate Participants: Courtney O'Konek -- Senior Director of Corporate Communications and Investor Relations Mark
Acasti Pharma (ACST): Q3 2020 Earnings Snapshot
-- Acasti Pharma Inc. (NASDAQ: ACST) reported Q3 2020 net loss of CAD15.7 million, or CAD0.18 per share, compared to net loss
AbbVie (ABBV) Q4 earnings preview: Generic competition might weigh on results
With only a few weeks left for closing the high-value acquisition of Allergan, AbbVie (NYSE: ABBV) is busy doing the groundwork for
Amgen’s (AMGN) Q4 results beat estimates
Amgen Inc. (NASDAQ: AMGN) topped revenue and earnings estimates for the fourth quarter of 2019. However, shares fell 2.7% in aftermarket hours
Biogen (NASDAQ: BIIB): Q4 2019 Earnings Snapshot
-- Biogen Inc. (NASDAQ: BIIB) reported its fourth-quarter 2019 adjusted earnings of $8.34 per share versus $8.02 per share expected. -- Total
Pfizer beats Q4 revenue estimates; earnings miss expectations
Pfizer Inc. (NYSE: PFE) topped revenue expectations for the fourth quarter of 2019 while earnings missed the mark. Shares fell 1.6% in
Key factors to note when Pfizer (PFE) reports Q4 earnings results
Pfizer Inc. (NYSE: PFE) is scheduled to report fourth quarter 2019 earnings results on Tuesday, January 28, before the market opens. Both
Abbott Laboratories (ABT) reports in-line earnings for Q4; guides FY20
Abbott Laboratories (NYSE: ABT) reported a marked increase in fourth-quarter earnings as the drugmaker's strong product portfolio boosted sales in the key